Skip to content

Itm2b Amyloidosis C0268393

Published: July 22, 2026Updated: August 20, 2026

Itm2b Amyloidosis is a genetic disorder where abnormal proteins build up in brain blood vessels, leading to progressive decline. It causes dementia and neurological problems. Care focuses on symptom management and support.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Progressive cognitive decline

(neurologic)

Gait ataxia

(neurologic)

Visual disturbances

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Neuroimaging surveillance

Periodic MRI or CT imaging of the brain to detect cerebral amyloid deposition, microbleeds, or white matter changes characteristic of ITM2B-related hereditary cerebral amyloid angiopathy.

monitoring
3

Blood pressure management

Aggressive antihypertensive therapy to maintain optimal blood pressure, reducing the risk of hemorrhagic stroke which may be increased in cerebral amyloid angiopathy.

medication

Additional treatment options

Symptomatic seizure management

Anticonvulsant therapy for patients experiencing seizures secondary to cortical involvement, selected to avoid medications that lower seizure threshold.

medication

Fall prevention strategies

Home safety assessment and modification to reduce head injury risk, including removal of fall hazards, installation of grab bars, and balance training exercises.

lifestyle

Cognitive and neuropsychological support

Neuropsychological evaluation and ongoing cognitive support services to monitor for progressive cognitive changes and provide compensatory strategies.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Itm2b Amyloidosis C0268393?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Itm2b Amyloidosis C0268393. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy